Results from a trial of an mRNA vaccine for pancreatic cancer have shown that the vaccine reduces the chance of the cancer ...

A clinical trial from Memorial Sloan Kettering Cancer Center looked at the effects of a targeted mRNA vaccine on early-stage ...

A personalized mRNA vaccine appeared to reduce the chances of pancreatic cancer returning after surgery, according to a study ...

There is new hope in the fight against pancreatic cancer after early trials showed that personalized mRNA vaccines can target ...

In a small trial, nearly half of pancreatic cancer patients who received an mRNA vaccine for the disease had no relapse three ...

A Memorial Sloan Kettering phase 1 clinical trial revealed an immune response in some pancreatic cancer patients. Study ...

"GMA" examines a preliminary study where a personalized mRNA vaccine showed promise in reducing the risk of pancreatic cancer ...

A personalized mRNA vaccine may reduce the risks of pancreatic cancer returning after surgery, according to a preliminary study published Wednesday in the journal Nature. Pancreatic cancer is one ...

In a small trial, 8 of 16 patients responded well to the mRNA vaccine The vaccine is personalized, based on each patient’s ...

The phase 1 trial results, published Feb. 19 in Nature, evaluated the personalized mRNA neoantigen vaccine autogene cevumeran in combination with surgery, immunotherapy drug atezolizumab and ...

The trial would combine standard surgery and chemotherapy treatments — which are the standard of care for pancreatic cancer — with a customized mRNA vaccine. Each vaccine would be designed ...

A vaccine for pancreatic cancer could serve as a promising new therapy. At Memorial Sloan Kettering Cancer Center (MSK) in New York, an experimental approach to treating the cancer with a ...